You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)上半年純利18.42億元 同比增長150.3%
格隆匯 08-23 16:40

格隆匯8月23日丨藥明生物(02269.HK)發佈公吿,截至2021年6月30日止6個月,實現收益人民幣44.068億元,同比增長126.7%;毛利人民幣22.968億元,同比增長191.7%;公司擁有人應占純利人民幣18.421億元,同比增長150.3%;基本每股盈利人民幣0.44元。

報吿期內,集團再次超額完成業績目標。憑藉其行業領先的賦能平台,集團繼續成功實施“贏得分子”策略,為加速及轉變生物藥(特別是COVID-19藥物及疫苗)的發現、開發及生產提供端到端解決方案。

根據披露,綜合項目數由去年同期的286個,增長42.7%至2021年6月30日的408個;臨牀前項目數由去年同期的141個,增長50.4%至2021年6月30日的212個;早期(第I及II期)臨牀開發項目數由去年同期的125個,增長28.0%至2021年6月30日的160個(其中I期項目116個、II期項目44個);後期(第III期)臨牀開發項目數由去年同期的19個,增長68.4%至2021年6月30日的32個,為啟動更多的商業化生產項目奠定基礎;集團在報吿期內新增兩個商業化生產項目;集團成功將更多項目從IND前階段進展至IND後階段:報吿期內,14個項目已由臨牀前開發階段進入早期臨牀開發階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account